Zura Bio Limited

NasdaqCM ZURA

Zura Bio Limited Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Zura Bio Limited Operating Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
NasdaqCM: ZURA

Zura Bio Limited

CEO Mr. Robert Lisicki
IPO Date March 21, 2023
Location United States
Headquarters 4225 Executive Square
Employees 14
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

StockViz Staff

January 15, 2025

Any question? Send us an email